Asciminib Proves Safety in Newly Diagnosed CML

Fadi Haddad, MD, an assistant professor and co-leader of the Section of Chronic Myeloid Leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from an ongoing phase 2 trial (NCT06236724) investigating asciminib (Scemblix) in patients with newly diagnosed chronic myeloid leukemia at the 2025 ASH Annual Meeting & Exposition.

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a third of the patients achieved deep molecular remission. Overall, Haddad described asciminib as being a safe drug with low-grade adverse events.